Catalyst Pharmaceuticals’ (CPRX) Overweight Rating Reiterated at Stephens

Stephens reaffirmed their overweight rating on shares of Catalyst Pharmaceuticals (NASDAQ:CPRX) in a research report report published on Thursday morning,Benzinga reports. They currently have a $33.00 price objective on the biopharmaceutical company’s stock.

Other equities analysts have also issued reports about the stock. Truist Financial boosted their price target on shares of Catalyst Pharmaceuticals from $30.00 to $36.00 and gave the stock a “buy” rating in a research report on Monday, November 11th. Bank of America restated a “buy” rating and set a $30.00 price target on shares of Catalyst Pharmaceuticals in a research report on Thursday, January 9th. HC Wainwright boosted their price target on shares of Catalyst Pharmaceuticals from $30.00 to $35.00 and gave the stock a “buy” rating in a research report on Friday, January 10th. Baird R W upgraded shares of Catalyst Pharmaceuticals to a “strong-buy” rating in a research report on Monday, February 3rd. Finally, Robert W. Baird started coverage on shares of Catalyst Pharmaceuticals in a research report on Tuesday, February 4th. They set an “outperform” rating and a $28.00 price target on the stock. Eight analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Buy” and a consensus price target of $32.00.

Catalyst Pharmaceuticals Stock Up 5.7 %

CPRX stock opened at $22.89 on Thursday. The stock has a market capitalization of $2.73 billion, a P/E ratio of 19.40, a P/E/G ratio of 3.31 and a beta of 0.80. The firm has a 50-day simple moving average of $22.24 and a 200-day simple moving average of $21.43. Catalyst Pharmaceuticals has a 52 week low of $14.47 and a 52 week high of $24.64.

Insider Buying and Selling at Catalyst Pharmaceuticals

In other Catalyst Pharmaceuticals news, insider Steve Miller sold 50,000 shares of the business’s stock in a transaction dated Tuesday, December 10th. The shares were sold at an average price of $21.93, for a total value of $1,096,500.00. Following the transaction, the insider now directly owns 686,996 shares in the company, valued at $15,065,822.28. The trade was a 6.78 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. 11.00% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Catalyst Pharmaceuticals

Several large investors have recently made changes to their positions in the stock. Summit Investment Advisors Inc. lifted its holdings in shares of Catalyst Pharmaceuticals by 5.2% in the 4th quarter. Summit Investment Advisors Inc. now owns 11,696 shares of the biopharmaceutical company’s stock worth $244,000 after acquiring an additional 580 shares during the last quarter. Bank of Montreal Can lifted its holdings in shares of Catalyst Pharmaceuticals by 6.2% in the 4th quarter. Bank of Montreal Can now owns 14,879 shares of the biopharmaceutical company’s stock worth $311,000 after acquiring an additional 875 shares during the last quarter. Rhumbline Advisers lifted its holdings in shares of Catalyst Pharmaceuticals by 0.3% in the 4th quarter. Rhumbline Advisers now owns 312,320 shares of the biopharmaceutical company’s stock worth $6,518,000 after acquiring an additional 952 shares during the last quarter. Handelsbanken Fonder AB lifted its holdings in shares of Catalyst Pharmaceuticals by 2.9% in the 4th quarter. Handelsbanken Fonder AB now owns 35,477 shares of the biopharmaceutical company’s stock worth $740,000 after acquiring an additional 1,000 shares during the last quarter. Finally, PDT Partners LLC lifted its holdings in shares of Catalyst Pharmaceuticals by 5.2% in the 4th quarter. PDT Partners LLC now owns 20,664 shares of the biopharmaceutical company’s stock worth $431,000 after acquiring an additional 1,030 shares during the last quarter. 79.22% of the stock is currently owned by institutional investors and hedge funds.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.